Industry News

Philips India and Ion Beam Applications S.A. (IBA), a global leader in proton therapy for the treatment of cancer, signed an exclusive agreement to enhance access to proton therapy in India. The collaboration also enables both organizations to mutually leverage technologies and solutions. Two companies have already signed multiple country-specific collaboration agreements, each optimized for the local market needs.The alliance combines Philips’ expertise and innovative imaging techniques for strengths in proton therapy.

Jubilant Life Sciences, one of the leading players in nutrition market and the largest manufacturers of vitamin B3 (Niacin and Niacinamide) in the world, announced a price increase of 10 per cent for Niacinamide, with immediate effect, for non-contract customers and wherever existing contracts permit. Niacin and niacinamide are forms of vitamin B3 and used in various pharmaceutical products.

The Dadha Group launched NetMeds.com. Netmeds is the “first-to-market” offering a consolidated, Pan-Indian solution for the quick online purchase and ensured fast delivery of prescriptions medications.  India’s first e-marketplace for pharma in the form of a portal  which offers an impressive selection of both prescription drugs and non-prescription products (OTC) drugs, supplying over 25,000 stock keeping units (SKUs) across India from its first warehousing hub in Chennai.  Prescription medication users will have opportunity to select their required medications from more than 260 drug categories for the chronic conditions, such as diabetes, hypertension and cholesterol control.

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, generics, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery.  US Food and Drug Administration (USFDA) upgraded Jubilant Hollisterstier's pharmaceutical sterile manufacturing facility in Spokane, Washington (USA)  to the status of Voluntary Action Indicated (VAI). This upgradation by the USFDA from Official Action Indicated (OAI) to VAI is indicative of the cGMP status at the facility since receiving the warning letter in 2013.

Glenmark Pharmaceuticals Inc., USA (Glenmark) get final approval by the United States Food & Drug Administration (FDA) for calcipotriene cream, 0.005 per cent, the therapeutic equivalent of Dovonex cream, 0.005 per cent of Leo Pharma A/S.  Glenmark strategy to start to shipping of calcipotriene cream, 0.005 per cent immediately.

Horizon Discovery Group plc, UK translational genomics company developing and supplying patient-relevant drug discovery and diagnostic research toolsand DefiniGEN Ltd, a leading provider of stem cell products and services, have entered into a collaboration to develop a range of unique, gene-engineered iPS (induced pluripotent stem)-based cell lines for use in research.

[adsense:336x280:8701650588]

Romaco Group,  a leading global supplier of processing and packaging equipment, will be present the first ever anti-counterfeit solution for blister packs at ACHEMA, Frankfurt/Main (Germany), from June 15 to 19, 2015. The new system was developed exclusively with its partner company NANO 4 U. The system can be incorporated into all blister machines equipped with coding stations and will be showcased at Achema in a Romaco Noack line 960. The blisters feature a NANO4U hologram stamp which can incorporate a hidden logo or code, as well as other covert and overt safety features.

Multiplicom N.V., develops, manufactures and commercializes molecular diagnostic assays, launched two kits-- the BRCA Hereditary Cancer MASTR Plus kit and the BRCA Tumor MASTR Plus kit, to screen hereditary breast and ovarian cancers. The BRCA Hereditary Cancer MASTR kit detects germline variants in 26 genes associated with hereditary cancers and the BRCA Tumor MASTR Plus is used for detection of variants in BRCA1 and BRCA2 in tumour biopsy material.

The US Food and Drug Administration (FDA) has granted orphan-drug designation to biopharmaceutical company MediciNova Inc.'s MN-166 (ibudilast) for treatment of Krabbe disease. MediciNova previously opened an Investigational New Drug (IND) application with the Division of Neurology Products (DNP) for MN-166 (ibudilast).